Skip to main
IMCR
IMCR logo

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 14%

Bulls say

Immunocore Holdings PLC has established a positive growth trajectory through its ImmTAX platform, which underpins a robust pipeline targeting multiple therapeutic areas including oncology, infectious diseases, and autoimmune disorders. The company's lead product, KIMMTRAK, has demonstrated strong market performance by surpassing sales expectations in 12 out of 14 quarters since its FDA and EMA approvals in early 2022, indicating solid demand and acceptance in the market. While US market penetration is anticipated to plateau at 68% by mid-2025, growth prospects are supported by increased treatment durations and potential international launches, bolstering the company’s long-term outlook.

Bears say

The financial outlook for Immunocore Holdings appears negative due to disappointing clinical trial results for its key product, KIMMTRAK, which reported low overall response rates of 11% in cutaneous melanoma and 6% in ovarian cancer, failing to meet market expectations. Additionally, the company faces significant competitive pressure from emerging therapies, such as IDYA's darovasertib, which could negatively impact KIMMTRAK's market potential in the HLA-A2+ metastatic uveal melanoma segment. These factors combined suggest a challenging environment for Immunocore Holdings as it attempts to navigate a competitive landscape while depending on underperforming trial data.

Immunocore Holdings (IMCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 14% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 7 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.